Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, forecasts that Eli Lilly's Strattera (atomoxetine) will account for 25% of the total child and adult Attention-Deficit/Hyperactivity Disorder (ADHD) drug sales in the seven major markets (United States, France, Spain, Italy, Germany, United Kingdom, Japan) in 2006.

(Photo: )

"Atomoxetine is poised to become a key player in the ADHD market over the next ten years. Although stimulants such as methylphenidate are highly effective, physicians and parents have been looking forward to the arrival non-stimulant alternatives like atomoxetine," said Nicky Lowney, analyst at Decision Resources. "Although atomoxetine faces generic price competition after 2006, it will also find increased uptake in new markets during this time."

About Strattera (Atomoxetine)

The U.S. Food and Drug Administration (FDA) recently approved atomoxetine (Strattera) for the treatment of ADHD in children, adolescents, and adults. It is the first FDA-approved treatment for ADHD that is not a stimulant under the Controlled Substances Act.

About Decision Resources

Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The company provides strategic information services, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

   For more information, contact:     Elizabeth Marshall    Decision Resources    781-296-2563 


Photo: NewsCom:

AP Archive:

PRN Photo Desk, 888-776-6555 or 212-782-2840

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, +1-781-296-2563,

Increasing Antibiotic Resistance Crisis A Major Contributor to Infections Acquired by Patients During Hospital Stays

View Now